Showing 1 - 2 results of 2 for search 'Costas K. Yannakou', query time: 0.02s Refine Results
  1. 1
    Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS

    Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS by Gareth P. Gregory, Michael Dickinson, Costas K. Yannakou, Jonathan Wong, Piers Blombery, Greg Corboy, Lev Kats, Tim M.E. Crozier, Beena Kumar, H. Miles Prince, Stephen S. Opat, Jake Shortt

    Published 2019-04-01
    Get full text
    Article
  2. 2
    S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

    S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/... by Rosa Ayala, Nieves Lopez, Adi Shacham Abulafia, Maan Alwan, Costas K. Yannakou, Indu Raman, Vincent Ribrag, Chun Yew Fong, Yulia Volchek, Massimiliano Bonifacio, Alessandra Tucci, Jean-Jacques Kiladjian, Jésus Marïa Hernandez Rivas, Blanca Xicoy, Haifa Kathrin Al-Ali, Jean-Christope Ianotto, Si Tuen Lee-Hoeflich, Sharmilla Das, Bin Wu, Palanikumar Ravindran, Qian Zhao, Guan Wang, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, David Lavie

    Published 2023-08-01
    Get full text
    Article

Search Tools: